開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN TRIAL OF ALK-1 IN COMBINATION WITH KN046 IN ADVANCED OR REFRACTORY SOLID TUMORS

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that the Company has enrolled and dosed its first patient with advanced or refractory solid tumors in a phase Ib/II clinical trial (the "**Clinical Trial**") of ALK-1 antibody (GT90001) in combination with KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody invented and developed independently by Alphamab Oncology (stock code: 9966.HK), in Taiwan, China.

The Clinical Trial (NCT04984668) is a two-stage, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ALK-1 antibody in combination with KN046 in patients with advanced or refractory solid tumors (including hepatocellular carcinoma (HCC), gastric carcinoma (GC), gastroesophageal junction (GEJ) adenocarcinoma, urothelial carcinoma (UC) and esophageal square cell carcinoma (ESCC)).

ALK-1 antibody is a fully human IgG2 neutralising monoclonal antibody that inhibits ALK-1/TGF-β signal transduction and tumor angiogenesis and a potential first-in-class antibody for which the Company obtained an exclusive global license for all the oncological areas from Pfizer, Inc. in February 2018.

Previously, phase II clinical trial of the combination therapy of ALK-1 antibody and Nivolumab on patients with advanced hepatocellular carcinoma ("**HCC**") has started in Taiwan, China, the preliminary data of which showed positive efficacy and safety results and has been released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The overall response rate was 40%. On 11 February 2021, the multiregional phase II clinical trial of combination therapy of ALK-1 antibody and Nivolumab for the second-line treatment of advanced HCC was greenlighted by the United States Food and Drug Administration. On 9 October 2021, the clinical trial of combination therapy of ALK-1 antibody and Nivolumab for the first-line treatment of advanced HCC was approved by the National Medical Products Administration of China. For further details, please refer to the announcements of the Company dated 9 December 2020, 18 February 2021 and 11 October 2021 respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that ALK-1 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 2 November 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*